Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring
- 1 October 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (10) , 4575-4580
Abstract
Virological residual activity (VRA) denotes the degree of HIV RNA suppression achieved by antiretroviral therapy in the presence of resistant virus. This concept is particularly important in resource-limited settings, where rapid switching after detection of virological failure may not be feasible. Using data from the NORA trial, we estimated VRA for two regimens—zidovudine-lamivudine-abacavir (ZDV-3TC-ABC) and zidovudine-lamivudine-nevirapine (ZDV-3TC-NVP)—and related this to the phenotypic drug sensitivity of the component drugs in the two regimens. Plasma samples at weeks 0, 48, and 96 were retrospectively assayed for HIV-1 RNA, and genotypic/phenotypic resistance testing was performed if HIV-1 RNA exceeded 1,000 copies/ml. Virological residual activity (VRA) was defined as the difference between log10(HIV RNA) at week 48 or 96 and week 0 and related to 50% inhibitory concentration (IC50) relative to wild-type virus for ZDV and ABC (fold change [FC]). Twenty-seven samples in the ZDV-3TC-NVP group and 56 in the ZDV-3TC-ABC group contributed to the analysis. Mean VRA was significantly higher in the ZDV-3TC-ABC group than in the ZDV-3TC-NVP at week 48 (1.62 versus 0.90) and week 96 (1.29 versus 0.78). There was a weak and nonsignificant relationship between VRA and ZDV FC, with VRA decreasing by 0.1 log10copies/ml per 2-fold increase in ZDV. The association with ABC FC was much stronger, with a marked reduction in VRA occurring at ABC FC values greater than approximately 2. This information should be considered in future treatment guidelines relevant to resource-poor settings.Keywords
This publication has 30 references indexed in Scilit:
- Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell countsHIV Medicine, 2010
- Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trialThe Lancet, 2010
- Relation between HIV viral load and infectiousness: a model-based analysisThe Lancet, 2008
- Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus InfectionJournal of Virology, 2008
- Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/μlAIDS, 2008
- Twenty‐four‐week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first‐line antiretroviral therapy: a randomized double‐blind trial (NORA)*Tropical Medicine & International Health, 2008
- Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptaseAIDS, 2007
- Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIsJournal of Clinical Microbiology, 2003
- Changes in Virologic Markers as Predictors of CD4 Cell Decline and Progression of Disease in Human Immunodeficiency Virus Type 1‐Infected Adults Treated with NucleosidesThe Journal of Infectious Diseases, 1998
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995